Close Menu

peripheral artery disease

Some of the loci suggest potential treatment options with drugs that modulate LDL cholesterol, the LPL pathway, or circulating lipoprotein(a), the researchers said.

Through a genome-wide association study, a team of researchers from Riken uncovered three loci linked to peripheral artery disease susceptibility.

On a conference call last month following the release of its Q1 earnings, Vermillion CEO Thomas McLain announced that the company would be taking over from Quest Diagnostics as leader of commercialization efforts for its OVA1 ovarian cancer diagnostic (

Vermillion this week sent Quest Diagnostics a notice of default under the companies' Strategic Alliance Agreement relating to Vermillion's OVA1 and Vasclir diagnostic tests.

This story has been update to include comments from a Vermillion executive.

Vermillion this week reported essentially flat revenues for the third quarter of 2012 compared to the year-ago period.

This article has been updated from a version posted Oct. 12 to include additional information.

Vermillion last week reported results demonstrating the utility of its Vasclir protein biomarker test for peripheral artery disease.

This story originally ran on May 16.
Vermillion this week reported first-quarter 2012 revenues of $312,000, down 28 percent from $431,000 a year ago.

This story originally ran on Feb. 29 and has been updated to include comments from an investor.
By Adam Bonislawski

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.